# Alida Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alida-biosciences

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.alidabio.com
- Total disclosed funding: $7.5M
- Latest round: Series A (Jun 7, 2024)
- Investors on record: 3

## About

Based in California, US, and founded in 2020 by Byron Purse and Gudrun Stengel, Alida Biosciences Inc., a.k.a. Alida Bio operates as a biotechnology company that focuses on developing RNA analysis tools to enable new medical treatments and diagnostic assays. The company’s technology enables the study of gene regulation processes by simultaneously detecting multiple epigenetic markers. In June 2024, Alida Biosciences Inc. raised USD 7.5 million in a Series A funding led by Genoa Ventures, with participation from FusionX Ventures and Vertical Venture Partners.

Alida Bio's flagship product is the EpiPlex™ Library Prep Kit, designed for multiplexed detection of RNA modifications in mRNA and long ncRNA. EpiPlex™ Library Prep Kit uses sequencing to provide detailed information on RNA modifications, including identity, location, and quantity. Alida Bio also offers tailored solutions and comprehensive analyses for various sectors, including pharmaceuticals and diagnostics. The firm’s proprietary bioinformatics pipeline enhances data interpretation, providing insights for scientific and clinical research.

The company plans to use its proceeds from June 2024 funding to support product development.

## Funding rounds

- Series A, Jun 7, 2024, $7.5M — Vertical Venture Partners, Genoa Ventures, FusionX Ventures

## Investors

- Vertical Venture Partners (https://capitalatlas.ai/funds/vertical-venture-partners) — Series A
- Genoa Ventures (https://capitalatlas.ai/funds/genoa-ventures) — Series A
- FusionX Ventures (https://capitalatlas.ai/funds/fusionx-ventures) — Series A